Title:

Hospital outcomes in interstitial lung disease-related admissions: a multicentre retrospective study in the North West of England.

Author List and Affiliations

Authors

First Author: Dr. Laura White[1,2]

Dr. Jonathon Shaw[3]

Dr. Bethan Powell[4]

Dr. Nyan May Kyi[5]

Dr. Alicia Sou[6]

Dr. Gareth Hughes[7,8,9]

Dr. Dilanka Tilakaratne[7]

Dr. Conal Hayton[10, 11]

Dr. Trishala Raj[10]

Dr. Vi Truong[12]

Dr. Nashwah Ismail[12]

Dr. Nawat Khanijoun[12]

Dr. Rebecca Huang[13]

Dr. Emma Hardy[13]

Dr. Mahzaib Babar[13]

Dr. Naayaab Khan[13]

Dr. Martin Regan[13]

Dr. Oby Okpala[13]

Dr. Ragavilasini Suresh[13]

Dr. Jerome McIntosh[13]

Dr. Amsal Amjad[13]

Dr. Mahum Sohail[13]

Dr. Zainab Aslam[13]

Dr. Amy Gadoud[1]

Dr. Timothy Gatheral[1,2]

Last Author: Dr. Georges NgManKwong[5]

Affiliations

1. Lancaster Medical School, Lancaster University, Lancaster, UK.

2. Department of Respiratory Medicine, Royal Lancaster Infirmary, University Hospitals of Morecambe Bay NHS Foundation Trust, Lancaster, UK.
3. Department of Respiratory Medicine, Stockport NHS Foundation Trust, Stockport, UK.
4. Department of Respiratory Medicine, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK.
5. Department of Respiratory Medicine, The Royal Oldham Hospital, Northern Care Alliance NHS Foundation Trust, Greater Manchester, UK.
6. Department of Respiratory Medicine, Fairfield General Hospital, Northern Care Alliance NHS Foundation Trust, Greater Manchester, UK.
7. Department of Respiratory Medicine, Bolton NHS Foundation Trust, Bolton, UK.
8. Division of Infection, Immunity & Respiratory Medicine, The University of Manchester, Manchester, UK
9. School of Health, Science and Society, University of Greater Manchester, Bolton, UK
10. Department of Respiratory Medicine, Wythenshawe Hospital, Manchester University Hospitals NHS Foundation Trust, Greater Manchester, UK.
11. School of Medical Sciences, University of Manchester, Manchester, UK.
12. Department of Respiratory Medicine, Manchester Royal Infirmary, Manchester University Hospitals NHS Foundation Trust, Greater Manchester, UK.
13. Department of Respiratory Medicine, Tameside General Hospital, Tameside and Glossop NHS Foundation Trust, Greater Manchester, UK.

Corresponding Author

Dr. Laura White
Lancaster Medical School
Lancaster University
Bailrigg
Lancaster
LA1 4YW
Email: laurajanewhite@doctors.org.uk

Abstract

Background. Interstitial lung diseases (ILD) are a heterogenous group of often progressive diseases which follow an unpredictable disease course. They frequently result in hospitalisations secondary to respiratory decompensations, termed ILD-related admissions. A proportion of these

are due to an acute exacerbation (AEILD) – a clinically and radiologically significant event. All are associated with high mortality but are poorly characterised in real-world populations.

Aim. To evaluate mortality outcomes and associated risk factors following ILD-related hospital admissions in a UK multicentre cohort.

Methods. We conducted a multicentre retrospective cohort study of primary ICD10 coded admissions for ILD between 01.01.2017 and 31.12.2019 across 11 NHS hospitals in the North West of England. AEILD events were classified with clinical criteria based on a <30-day respiratory deterioration not secondary to cardiac failure, pulmonary embolism or pneumothorax. Primary outcome was time from admission to death. Statistical analyses included Kaplan-Meier survival and multivariate cox proportional hazards modelling.

Results. Of 938 admissions ILD-related admissions, 54.5% met AEILD criteria. Inpatient and 90-day was 16.0% and 40.2% respectively. Mean survival of the AEILD cohort was 439.91 days (95% CI 365.10 – 502.72 days) and other cohort 691.25 days (95% CI 599.60 – 782.90 days), with a statistically significant difference in survival ($p < 0.001$). AEILD and pre-admission oxygen use were consistently associated with increased mortality. Conversely, White and Asian ethnicity were associated with reduced risk of 90-day all-cause mortality. Only 13.9% of admissions had documented palliative care input.

Conclusion. This is the one of the largest datasets assessing ILD-related admission outcomes. AEILD events were common and independently associated with high mortality. Findings highlight the need for earlier palliative involvement, improved risk stratification and targeted AEILD-specific research.

Take Home Message

Hospitalised patients with interstitial lung disease, especially in the context of acute exacerbations, face significant short-term mortality. This study identifies associated risk factors and highlights opportunities for early palliative care involvement.

Disclaimers

The views expressed in the submitted article are our own and not an official position of the affiliated institutions or the Northern Care Alliance NHS Foundation Trust.

Sources of Support

LW has funding from the NIHR as an Academic Clinical Fellow to fund 25% research time within her job plan.

The Northern Care Alliance NHS Foundation Trust provided sponsorship of the study. There was no monetary support attached to this.

Contributorship

LW and GNgMK conceptualised the study and completed the ethics application.

LW was the lead investigator for the study, completed the analysis and wrote the manuscript.

All other authors completed data collection and provided feedback on the manuscript.

AG and TG are LW's academic supervisors and provided support with development of this manuscript.

LW is the corresponding author.

Data Sharing Statement

The anonymised data supporting the findings of this study are available from the corresponding author upon reasonable request.

AI Use Statement

There has been no use of AI in the development of this study or manuscript.

Ethics

The study was approved by the Health Research Authority (reference 23/HRA/4562). Further approval from a Research Ethics Committee was not required due to use of retrospective secondary data. Secondary data was managed and used as per GDPR guidelines.

Conflicts of Interest

No conflicts of interest to declare.

Introduction

Interstitial lung diseases (ILD) represent a heterogenous group of disorders affecting the lung parenchyma, causing a spectrum of disease from inflammation to fibrosis.[1] The UK has the highest number of patients with ILD in Europe with an approximate incidence of 4.6 – 8.65 per 100,000 people per year.[2] The trajectory of disease is variable, but often results in hospitalisation secondary to respiratory decompensation. Hospital admission in ILD is associated with significant morbidity and mortality.[3][4] A sub-set of these admissions are secondary to an acute exacerbation (AEILD). An AEILD is defined clinically by a less than 30-day deterioration in symptoms not secondary to thromboembolic, cardiac or pneumothorax events. Radiologically they are defined via high resolution computerised tomography (HRCT) evidence of bilateral ground-glass changes superimposed on a chronic ILD.[5] While this was initially defined amongst a cohort of patients with idiopathic pulmonary fibrosis (IPF), it has been extrapolated more recently to encompass all ILDs. Retrospective data has estimated annual incidence of AEILD at 9%, with AE-ILD events accounting for 41% of ILD-related admissions.[6][7]

It has been increasingly recognised that ILD-related hospital admissions have a significant impact on disease trajectory, with both high inpatient and 90-day mortality rates observed.[4][8][9][10] However, there is limited worldwide data reporting ILD-related admission outcomes. Management of ILD-related hospitalisations and AEILD events are currently guided by international consensus statements based on expert opinion. These statements recommend supportive interventions, although the scope of recommendations are limited due to a lack of robust evidence.[11][12] At present, only one negative randomised control trial in the treatment of AEILD has been published[13] and there is a major need to increase research capacity in AEILD.[14]

We aimed to understand the role of hospitalisation in ILD all-cause mortality using real-world data from the North West of England. A secondary aim was to understand the risk factors associated with all-cause mortality. Through understanding admission-related all-cause mortality in ILD, we can hope to identify research and service priorities.

Methods

Study Setting and Population

We performed a multicentre retrospective observational cohort study of ILD-related admissions in adults ≥18 years old using International Classification of Diseases Version 10 (ICD-10) coding across a 3-year period (1st January 2017 to 31st December 2019) from seven NHS trusts, encompassing 11 NHS secondary and tertiary hospitals, in the North West of England, covering an

estimated population of 7.3million people.[15] Figure 1 represents the geographical coverage and number of patients contributed by the 11 hospitals included in this dataset. ICD-10 codes of B22.1, D 86.0, D86.2, J67.0-67.9, J70.2-70.4, J84.1, J84.8 and J84.9 within the primary diagnosis of admission event triggered inclusion in the study. Admissions for attendance at day-case procedures, for provision of medications or lack of available medical records were excluded. Any prior documented dissent for use of data in research also resulted in exclusion. Figure 2 summarises the number of records identified, excluded and subsequently included in analysis in a CONSORT diagram.

1a)



1b)



1c)



Figure 1: *Choropleth map representing a) North West of England in geographical context of the UK, b) number of cases contributing to retrospective dataset from Greater Manchester and c) Lancashire and South Cumbria.*

Medical records were retrospectively reviewed, and hand searched between June 2024 and April 2025. The primary outcome was number of days from start of ILD-related admission to death.

Ethical approval for this study was granted by the Health Research Authority (HRA) for England and Wales (HRA reference: 23/HRA/4562). Given the retrospective nature of the study and anticipated high mortality rate, individual patient consent was not required. Only patients with previously recorded consent for the use of their data in research were included. Identifiable data was accessed and processed solely by site-specific clinicians who were part of the patients' direct care teams. All data was anonymised or pseudonymised at the point of site-level collection, in accordance with the General Data Protection Regulation (GDPR).[16]



Figure 2: *CONSORT study flow diagram summarising records identified, reasons for exclusion and number of records included in analysis.*
Abbreviations: ILD – interstitial lung disease; AEILD - acute exacerbation of interstitial lung disease.

Data Collection and Variables

Data collected was sourced from coding and through hand searching of medical records. Where available, data collection on demographics and pre-admission diagnoses included: age, gender, postcode, ethnicity, smoking history, co-morbidities, ILD diagnosis, pre-admission antifibrotic use, pre-admission oxygen use, pre-admission lung function tests (including forced vital capacity (FVC) and gas transfer factor (TLCO)). Comorbidities were converted to a Charlson Comorbidity Index (CCI) value.[17] Full postcodes were converted to deprivation deciles (DD), as per the 2019 UK Government English Indices of Deprivation data.[18] A DD of 1 represents the most deprived and 10 the least deprived.

Mortality-relevant data was obtained from coding and hand searching of inpatient medical records. This included: AEILD status, at-admission investigations (white cell count and differential, C-reactive protein (CRP), chest x-ray findings), whether any form of computerised tomography (CT) of the chest, echocardiogram and bronchoscopy were performed, and use of antibiotics or steroids throughout admission. Data on ventilatory support given, specialist respiratory and palliative reviews were also obtained from the notes.

Patients were allocated to an AEILD admission cohort or 'other' ILD-related hospital admissions cohort. AEILD status was determined by hand searching of medical records and investigations relating to the admission event. For the purposes of this study, we defined AEILD clinically only by <30-day clinical deterioration, not secondary to cardiac failure, thromboembolic disease (TED) or pneumothorax event. Hand-searching of the clinical narrative, biochemical investigations (negative pro-B natriuretic peptide (pro-BNP) and negative D-dimer, where available), radiological investigations (chest x-ray and CT pulmonary angiogram (CTPA), where available) and medical treatments determined this status. If a patient met this criterion, their admission was labelled 'AEILD' and if not, was labelled as 'other' ILD-related admission. Other ILD-related hospital admission reasons included disease progression, pulmonary embolism, cardiac failure secondary to pulmonary hypertension and pneumothorax. A respiratory review was considered a review from any respiratory-specialist healthcare professional. A palliative review was considered a review from any palliative-specialist healthcare professional.

The primary outcome was established by determining the number of days from admission start date to date of death and recorded as number of days.

Statistical Analysis

To power the study to achieve statistical significance, we used a predicted overall all-cause mortality of 60% in the follow-up period, a mortality-based model of ten predictors and an R-squared of 0.1 determined the inclusion of 850 admission events. We chose a multicentre, 3-year inclusion period to achieve this threshold.

All statistical analysis was undertaken using SPSS (Version 29.0.0.0 (241)) and verified using Python (v3.11), with the 'statsmodel' package for Cox proportional hazards modelling. Continuous observational data was analysed by mean (standard deviation). Categorical observational data was reported as frequencies (percentage). Admissions were grouped into AEILD or other primary admission based on clinical criterion defined above. Continuous data was assessed for normality using the Shapiro-Wilks test and then compared using the unpaired t-test or Mann-Whitney-U test dependent on presence of normal distribution. Categorical data was compared with the chi squared test or Fisher's exact test if the expected count was less than five. Post-hoc analysis of chi-squared with multiple comparisons was undertaken using standardised residuals, converted to P values and compared to the Bonferroni correction for statistical significance.

For time-to-event outcomes, Kaplan Meier survival analysis with log-rank comparison for 2 or more curves was undertaken. Mean and median survival were calculated. To quantify risk for all-cause mortality, hazard ratios with corresponding 95% confidence intervals were estimated using a multivariate Cox proportional hazards model using the ENTER method. Variables for the multivariate model were selected a priori and entered into the model simultaneously. Variable selection was informed by both clinical relevance and prior evidence, rather than data-driven stepwise methods, to minimise model overfitting. Demographic characteristics (e.g. age, gender, ethnicity) were included to assess the impact of non-modifiable risk factors, while clinical and inflammatory variables were chosen for their known or hypothesised relevance to mortality risk in ILD populations.[(3)(19)(20)] The proportional hazards assumption was checked using Schoenfeld residuals. Results yielding $p < 0.05$ were considered statistically significant.

Complete case analysis was undertaken. Variables with high proportions of missing data (>15%), once data collection had been undertaken, were removed. Variables subsequently taken into the multivariate model were gender, age, ethnicity, CCI, ILD subtype, pre-admission oxygen status, AEILD status, neutrophils, monocytes and CRP. FVC was originally planned to be included in the model but due to a high proportion of missing data (390/938 or 38.9%), it was replaced with pre-admission oxygen status.

Results

3451 admissions were identified. 2449/3451 (70.9%) of admissions were excluded. Reasons for exclusion are summarised in the CONSORT study flow diagram (figure 2) with the main reason for exclusion being day case procedures (1984/2449, 81.1%). The remaining 1002 admission events underwent hand-searching of medical records and medical coding data. 64/1002 (6.4%) had insufficient data available to determine AEILD vs. other ILD-related admission status, leaving 938 admissions for inclusion in analysis. Median follow-up amongst censored patients (those alive at the end of the study period) was 2125 days (range 1563 – 2968 days).

Descriptive Statistics

In total, 511/938 (54.5%) of admission events met clinical AEILD criteria as per the study definition and 427/938 (45.5%) were considered other ILD-related admissions. Other admissions included disease progression, cor pulmonale, pulmonary embolism and pneumothorax.

The baseline demographics of the overall, AEILD and other cohorts are summarised in table 1. Alongside demographic data, we report rates of CT use, respiratory specialist and palliative specialist reviews across the cohorts. These results are summarised in table 2.

	Overall n = 938	**AEILD Cohort n = 511**	**Other Cohort n = 427**	**P value**
Age *(Mean, SD)*	74.18 (12.48)	73.87 (11.63)	74.55 (13.42)	p = 0.058
Gender – Male *(Number, %)*	521 (55.5)	288 (56.4)	233 (54.6)	p = 0.582
Ethnicity *(Number, %)*				p = 0.067
Not stated	61 (6.5)	25 (4.9)	36 (8.4)	p = 0.153
White	802 (85.5)	444 (86.9)	358 (83.8)	p = 0.734
Asian	68 (7.2)	40 (7.8)	28 (6.6)	p = 0.624
CCI *(Mean, SD)*	4.46 (1.98)	4.38 (1.86)	4.54 (2.11)	p = 0.165
Deprivation Decile *(Mean, SD)*	4.62 (2.89)	4.62 (2.92)	4.63 (2.85)	p = 0.980
Ever-smoker *(Number, %)*	488 (52.0)	262 (51.3)	226 (52.9)	p = 0.786

ILD Subtype *(Number, %)*				**p <0.001***
Not stated	91 (9.7)	22 (4.3)	69 (16.2)	**p <0.001***
IPF	295 (31.4)	178 (34.8)	117 (27.4)	p = 0.174
NSIP	84 (9.0)	52 (10.2)	32 (7.5)	p = 0.358
CTD-ILD	46 (4.9)	28 (5.5)	18 (4.2)	p = 0.555
HP	77 (8.2)	44 (8.6)	33 (7.7)	p = 0.749
Drug-related	22 (2.3)	9 (1.8)	13 (3.0)	p = 0.390
Industry-related	19 (2.0)	10 (2.0)	9 (2.1)	p = 0.912
Sarcoidosis	25 (2.7)	11 (2.2)	14 (3.3)	p = 0.478
PFD	221 (23.6)	126 (24.7)	95 (22.2)	p = 0.610
Unclassifiable	28 (3.0)	18 (3.5)	10 (2.3)	p = 0.484
Other	30 (3.2)	13 (2.5)	17 (4.0)	p = 0.407
On antifibrotics *(Number, %)*	118 (12.6)	73 (14.3)	45 (10.5)	**p = 0.001***
Oxygen used pre-admission *(Number, %)*				**p = 0.013***
Long-term	256 (27.3)	153 (29.9)	103 (24.1)	p = 0.250
Ambulatory	78 (8.3)	50 (9.8)	28 (6.6)	p = 0.250
None	604 (64.4)	308 (60.3)	296 (69.3)	p = 0.246
FVC (L) *(Mean, SD)*	2.74 (11.83)	2.43 (5.08)	3.19 (17.66)	p = 0.089
TCLO (mmHg) *(Mean, SD)*	3.88 (2.19)	3.37 (1.61)	4.64 (2.67)	**p <0.001***

Table 1: *Summary of descriptive patient characteristics for overall, acute exacerbation of interstitial lung disease (AEILD) and other ILD-related admission cohorts. P-value refers to comparison between AEILD and other cohorts using independent T-test or Mann-Whitney-U test for continuous variables, and chi-squared or Fisher's exact test for categorical variables.*
Post-hoc analysis of chi-squared was undertaken using standardised residuals, converted to P values and compared to the Bonferroni correction for statistical significance.
Abbreviations: AE-ILD – acute exacerbation of ILD; CCI – Charlson Comorbidity Index; ILD – Interstitial Lung Disease; IPF – Idiopathic pulmonary fibrosis; NSIP – non-specific interstitial pneumonitis; CTD-ILD – connective tissue disease interstitial lung disease; HP – hypersensitivity pneumonitis; PFD – primary fibrosis as diagnostic label; SD – standard deviation.

	Overall n = 938	**AEILD n = 511**	**Other n = 427**
Any CT of thorax performed *Number (%)*	326 (34.8)	192 (37.6)	134 (31.4)
Respiratory Specialist Review *Number (%)*	508 (54.2)	350 (68.5)	158 (37.0)
Palliative Specialist Review *Number (%)*	130 (13.9)	92 (18.0)	38 (8.9)

Table 2: *Summary of number of patients receiving any type of CT scan to the thorax and inpatient respiratory specialist or palliative specialist review documented within medical records. Outputs reported as numbers (percentage of cohort).*

Abbreviations: CT – computerised tomography; AEILD – acute exacerbation of interstitial lung disease.

Primary Outcome – Mortality Rate and Time-to-Event Analysis

The overall all-cause inpatient and 90-day mortality for this cohort was 16.0% (150/938) and 40.2% (377/938). For the AEILD cohort, inpatient and 90-day all-cause mortality was 20.2% (103/ 511) and 47.6% (243/511) respectively. For the other ILD-related admission cohort, inpatient and 90-day all-cause mortality was 10.5% (45/427) and 31.4% (134/427) respectively. Table 3 summarises the observed mortality at each time interval.

	Overall **n = 938**	**AEILD** **n = 511**	**Other** **n = 427**
Death during inpatient admission *Number (%)* *Cumulative %*	150 (16.0) 16.0	103 (20.2) 20.2	47 (11.0) 11.0
Death within 30 days of discharge *Number (%)* *Cumulative %*	86 (9.2) 25.2	49 (9.6) 29.7	37 (8.7) 19.7
Death within 90 days of discharge *Number (%)* *Cumulative %*	141 (15.0) 40.2	91 (17.8) 47.6	50 (11.7) 31.7
Death >90 days from discharge *Number (%)* *Cumulative %*	473 (50.4) 90.6	239 (46.6) 94.1	235 (55.0) 86.4
Alive *Number (%)* *Cumulative %*	88 (9.4) 100.0	30 (5.9) 100.0	58 (13.6) 100.0

Table 3: *Summary of overall all-cause mortality at defined time intervals: during inpatient admission, within 30-days of discharge, within 90-days of discharge, >90 days of discharge and finally, remaining alive at point of secondary data collection. Outputs reported as numbers (percentage of cohort) and cumulative percentage).*
Abbreviations: AEILD – acute exacerbation of interstitial lung disease.

For the primary outcome, the mean and median survival of AEILD cohort was 439.91 days (95% CI 375.10 – 502.72 days) and 107 days (IQR 472 days) respectively. For the other ILD-related admission cohort, mean and median survival was 691.25 days (95% CI 599.60 – 782.90 days) and 169 days (IQR 775 days) respectively. The comparative difference survival between the two groups was statistically significant ($p < 0.001$; figure 3). Figure 3 represents the Kaplan Meier curve of all-cause mortality across the entire follow-up period.



***Figure 3**: Kaplan Meier with log rank comparative analysis of mortality outcomes from patients meeting clinical acute exacerbation of interstitial lung disease criteria vs. those admitted for other, interstitial lung disease-related pathologies. Mean and median survival of AEILD cohort was 439.91 days (95% CI 375.10 – 502.72 days) and 107 days respectively. Mean and medial survival of other ILD-related admission cohort was 691.25 days (95% CI 599.60 – 782.90 days) and 169 days respectively. Statistically significant difference in mean survival p <0.001.*
Abbreviations: AEILD – acute exacerbation of interstitial lung disease.

Secondary Outcome – Multivariate Cox Regression Analysis for Mortality Predictive Factors

We aimed to understand factors associated with all-cause mortality at two defined intervals: inpatient all-cause mortality and 90-day all-cause mortality. Results are summarised in table 4. Figure 4a-b represents forest plot summary of hazard ratios from the model.

	Inpatient All-Cause Mortality Multivariate HR (95% CI)	**P value**	**90-day All-Cause Mortality Multivariate HR (95% CI)**	**P value**
Age	1.022 (1.001 – 1.044)	**p = 0.043***	1.032 (1.017 – 1.046)	**p <0.001***
Gender Female Male	*Reference* 1.442 (0.993 – 2.094)	p = 0.054	*Reference* 1.35 (1.072 – 1.700)	**p = 0.011***

Ethnicity Not stated White Asian	 *Reference* 0.598 (0.323 – 1.106) 0.400 (0.150 – 1.063)	 p = 0.101 p = 0.066	 *Reference* 0.603 (0.396 – 0.916) 0.355 (0.188 – 0.668)	 **p = 0.018*** **p = 0.001***
CCI	0.989 (0.881 – 1.111)	p = 0.858	1.010 (0.938 – 1.087)	p = 0.794
ILD subtype Not known IPF NSIP CTD-ILD HP Drug-related Industrial (asbestosis, silicosis) Sarcoidosis PFD Unclassifiable Other	 *Reference* 1.186 (0.542 – 2.591) 0.866 (0.175 – 4.280) 1.576 (0.659 – 3.771) 0.625 (0.181 – 2.159) 0.372 (0.108 – 1.275) 1.723 (0.446 – 6.661) 0.961 (0.198 – 4.671) 0.965 (0.196 – 4.738) 1.055 (0.467 – 2.388) 1.321 (0.407 – 4.288)	 p = 0.670 p = 0.860 p = 0.307 p = 0.457 p = 0.115 p = 0.430 p = 0.961 p = 0.965 p = 0.897 p = 0.643	 *Reference* 1.039 (0.656 – 1.644) 0.557 (0.207 – 1.496) 1.278 (0.748 – 2.185) 0.713 (0.358 – 1.418) 0.242 (0.114 – 0.517) 0.776 (0.293 – 2.057) 0.471 (0.161 – 1.379) 0.899 (0.357 – 2.265) 0.802 (0.495 – 1.301) 1.106 (0.541 – 2.261)	 p = 0.871 p = 0.246 p = 0.370 p = 0.335 **p <0.001*** p = 0.610 p = 0.169 p = 0.821 p = 0.372 p = 0.782
Oxygen status None Long-term Ambulatory	 *Reference* 2.111 (1.451 – 3.073) 1.232 (0.634 – 2.393)	 **p <0.001*** p = 0.539	 *Reference* 1.965 (1.54 – 2.495) 1.384 (0.933 – 2.053)	 **p <0.001*** p = 0.107
AEILD status Other AEILD	 *Reference* 1.583 (1.086 – 2.308)	 **p = 0.017***	 *Reference* 1.490 (1.183 – 1.877)	 **p <0.001***
Neutrophil count	1.064 (1.017 – 1.114)	**p = 0.007***	1.077 (1.045 – 1.110)	**p <0.001***
Monocyte count	0.863 (0.560 – 1.330)	p = 0.505	0.889 (0.690 – 1.144)	p = 0.360
CRP	1.005 (1.003 – 1.007)	**p <0.001***	1.003 (1.001 – 1.004)	**p = 0.002***

Table 4 *– Summary table of multivariate Cox regression analysis on all-cause mortality at 2 defined time points: inpatient all-cause mortality and 90-day all-cause mortality. Statistically significant results are marked in bold and with an asterisk.*

Abbreviations: HR – hazard ratio; CCI –Charlson comorbidity index; ILD – interstitial lung disease; AEILD – acute exacerbation of interstitial lung disease; IPF – idiopathic pulmonary fibrosis; NSIP – non-specific interstitial pneumonitis; CTD-ILD – connective tissue disease interstitial lung disease; HP – hypersensitivity pneumonitis; PFD – primary fibrosis as diagnostic label; CRP – C reactive protein

4a)


Age
Male gender
White ethnicity
Asian ethnicity
Charlson Comorbidity Index
IPF
NSIP
CTD-ILD
HP
Drug-related
Industrial
Sarcoidosis
PFD
Unclassifiable
Other
Long-term oxygen use
Ambulatory oxygen use
AEILD
Neutrophil count
Monocyte count
CRP
0
1
2
3
4
5
6
Hazard Ratio
Reduced risk of mortality
Increased risk of mortality

4b)


Age
Male gender
White ethnicity
Asian ethnicity
Black ethnicity
Charlson Comorbidity Index
IPF
NSIP
CTD-ILD
HP
Drug-related
Industrial
Sarcoidosis
PFD
Unclassifiable
Other
Long-term oxygen use
Ambulatory oxygen use
AEILD
Neutrophil count
Monocyte count
CRP
0
1
2
3
4
5
Hazard Ratio
Reduced risk of mortality
Increased risk of mortality

Figure 4: *Forest plots showing adjusted hazard ratios (HRs) and 95% confidence intervals from multivariable Cox proportional hazards models for:*
a) Inpatient all-cause mortality; and
b) 90-day all-cause mortality
Abbreviations: IPF – idiopathic pulmonary fibrosis; NSIP – non-specific interstitial pneumonitis; CTD-ILD – connective tissue disease-interstitial lung disease; HP – hypersensitivity pneumonitis; PFD – pulmonary fibrosis as diagnostic label; AE-ILD – acute exacerbation of interstitial lung disease; CRP – c-reactive protein.

Discussion

Summary of Findings

This retrospective real-world dataset demonstrates a significant inpatient and 90-day all-cause mortality (16.0% and 40.2% respectively). The data demonstrates that AEILD conveys a statistically significant greater chance of mortality than those admitted for other ILD-related presentations. Alongside AEILD, pre-admission use of oxygen, male gender and raised neutrophils were associated with increased risk of all-cause mortality whereas White and Asian ethnicity and drug-related ILD were associated with reduced risk of all-cause mortality.

Role of AEILD in Mortality

AEILD events are not infrequent in the hospitalised ILD population. A prior retrospective study using clinical criterion only reported an AEILD rate of 52%[21] - similar to the rate we observed. In studies where radiological and clinical criterion were used, fulfilling “definite acute exacerbation” criteria set out by Collard el al,[22] the rate of AEILD in hospitalised patients was 20.8% - 41%.[7][23]

Not only are AEILDs frequent events, but they are associated with high mortality. Prior literature has reported mortality of up to 100% in the intensive care setting.[24] Our findings reinforce this high mortality: AEILD admissions were associated with significantly higher inpatient and 90-day mortality compared with other ILD-related admissions. Notably, median survival following AEILD admission was only 107 days, compared to 169 days for other ILD-related admissions. This difference remained significant even after multivariate adjustment, suggesting an AEILD event itself represents a distinct and high-risk clinical picture. However, there are a proportion of patients who survive beyond the 90-day mark for considerable periods, giving rise to the possibility of different phenotypes, causes and severities within the umbrella term AEILD. This hypothesis is supported by the observed differences in AEILD outcomes between differing ILD underlying disease types,[25] which is further suggested in our multivariate model – although not to a statistically significant degree. The possibility of differing AEILD severities was also addressed in a post-hoc analysis for exacerbators within the INPULSIS trial, with those meeting criteria for a serious adverse event demonstrating worse outcomes.[26]

The mechanisms driving poor outcomes in AEILD are poorly understood,[5] and treatment options remain limited.[11][14] The current international consensus guidance recommends supportive care but lacks specific pharmacological and non-pharmacological strategies.[22] Our results support the argument that AEILD represents not only an acute crisis but also a turning point in the disease course. The elevated mortality risk underscores the need for early identification, prompt multidisciplinary input, and targeted therapeutic trials in this population alongside clear, defined, palliative and end-of-life care strategies.

Reduced risk of mortality associated with White and Asian Ethnicity

In our multivariate analysis, when using "not stated" as a reference ethnicity, White and Asian ethnic backgrounds were associated with reduced risk of 90-day all-cause mortality. This finding aligns with UK public health epidemiological trends. In this data, the "ethnic paradox" is observed: where some ethnic minority groups, especially of South Asian background, have higher burden of chronic disease but paradoxically lower mortality rates.[27]

The impact of ethnicity on ILD outcomes has not yet been established. In a US population, ethnic disparities were observed across 4792 participants with pulmonary fibrosis. Black ethnicity was associated with diagnosis at a younger age, earlier hospitalisation and lung transplant but paradoxically lower mortality rates (when White ethnicity used as the reference category).[28] Several other studies mirror this finding of reduced mortality in ethnic minorities,[29] suggesting the complex interaction of social determinants of health, health-seeking behaviours, biological differences and cultural practices.

However, a challenge to this interpretation is the reference category of choice. This likely heterogenous group may be the result of inconsistent or incomplete ethnic coding, which has been shown to be unequally distributed in UK Office for National Statistics (ONS) data.[30] Ethnicity is often inconsistently recorded and analysed in UK health research – with little transparency on categorisation and choice of reference category.[31] In our dataset, ethnicity was derived from routine hospital coding and may not fully capture self-ascribed identity. The choice of "not stated" as the reference group reflects the constraints of the available data, and the fact the study was not specifically powered to explore ethnicity-based differences in depth. Our findings suggest a potential disparity that warrants further exploration, but also highlights the broader methodological challenges of analysing ethnicity in retrospective datasets in a potentially vulnerable subgroup. Future studies should prioritise more complete and consistent ethnicity data collection and be powered to explore subgroup differences meaningfully.

Palliative Care Input

Our study highlights a concerning underutilisation of specialist palliative care services in a population with exceptionally high short and long-term mortality – greater than many common cancers. Less than 1 in 5 patients experiencing an AEILD received inpatient specialist palliative care reviews despite a 90-day mortality of just under 50%. There have been several calls to improve access and use of palliative care services in ILD, with a growing understanding of the unmet needs of this population.[32][33][34] But a lower referral rate may reflect the clinical uncertainty ILD brings and the lack of direct palliative recommendations in the context of a respiratory decompensation or AEILD event.[22][35] This reflects the lack of evidence in this area, and, much of what is available being of low quality to base such recommendations on.[22] There is also a well-recognised international heterogeneity in approaches to AEILDs, with 50-71% of specialist clinicians reporting they routinely offer palliative care support in the context of ILD.[36]

In the UK, the National Institute for Clinical Excellence (NICE) care quality standard 5 for idiopathic pulmonary fibrosis (IPF) states: "people with IPF and their families and carers have access to services that meet their palliative care needs".[37] The recent British Thoracic Society (BTS) ILD registry report summarising 2024 data demonstrates the heterogeneity in meeting this care standard across UK hospitals,[38] further supported by our dataset findings. However, our study may underappreciate the palliative care provided by respiratory and general physicians. Our study recorded palliative care input as a documented inpatient review by a palliative care specialist only. More recent palliative-focused studies have shown the merits of a multidisciplinary team (MDT) model to improve patient-reported outcomes.[39] Follow-up studies should therefore look to include palliative care input from the wider MDT to improve our understanding of the use of palliative care approaches in the context of respiratory deteriorations and exacerbations.

Study Strengths and Limitations

To our knowledge, this study represents one of the largest looking at all ILD-related admission events and their mortality. It's multicentre design, encompassing several geographical regions and populations in the North-West of England enhance its power. By also including a mix of secondary and tertiary hospitals, these combined strengths increase the generalisability of the study – but limitations remain.

While our study is retrospective in nature, between the years of 2017 and 2019, this extended follow-up develops understanding of what happens to these patients in the longer-term – without the confounding variable of the COVID-19 pandemic. However, it is important to recognise the change in the treatment landscape in the period since this data collection, such as wider antifibrotic use,

which may impact patient outcomes. Follow-up studies should aim to obtain data prospectively to account for this.

The retrospective design also introduces the potential for recall and misclassification bias. This was particularly important for determining AEILD based on clinical, biochemical and radiological information available. While hand-searching notes and investigations aimed to mitigate misclassification bias, inter-rate reliability was not assessed. Alongside this, criteria to be considered an AEILD event was based on clinical information only – thus cohorts suspected AEILD events (no CT) and confirmed AE events (CT confirmed) together. Future studies may wish to separate these distinct entities in analysis. Missing data is also a further challenge of retrospective data, and we observed high rates of this when recording lung function testing (FVC and TLCO specifically). This high rate of missing data meant the need to remove FVC from our multivariate model. Additionally, hospital-only based data collection risks hospitalisation bias. Different results may be observed if respiratory decompensation events relating to ILD that don't result in hospital admission are also accounted for.

Despite covering a large geographic area in the North West of England, this study is region-specific and may not generalise to different health systems or ILD pathways observed outside of it. Further studies on a national scale, ideally with prospective data collection, are required to validate the results observed here.

Conclusion

This retrospective study demonstrates high mortality during and following ILD-related inpatient admissions, highlighting a research priority for the ILD community – especially within understanding AEILD, its risk factors, its management and mortality predictors. Our findings further cement the possibility of the ethnic paradox in ILD, but this needs validation within appropriately powered studies with accurate recording of ethnicity. This study emphasises that ILD-related admissions should prompt all clinicians to consider timely palliative care strategies to support quality-of-life and end-of-life care.

Acknowledgements

Thank you to the Northern Care Alliance NHS Foundation Trust for providing sponsorship of the study.

Thank you to the National Institute of Health and Social Care Research for the Academic Clinical Fellowship programme which afforded LW protected time to conduct this study.

Thank you to Professor Andy Vail for providing statistical guidance.

Ethics, Funding and Sponsorship

The study was approved by the Health Research Authority (reference 23/HRA/4562). Further approval from a Research Ethics Committee was not required due to use of retrospective secondary data. Secondary data was managed and used as per GDPR guidelines.

There was no funding associated with this study.

The study was sponsored by the Northern Care Alliance (NCA) NHS Foundation Trust.

References

1. Antoniou KM, Margaritopoulos GA, Tomassetti S et al. Interstitial lung disease. Eur Respir Rev. 2014;23(131):40–54.
2. Olson AL, Gifford AH, Inase N et al. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev [Internet]. 2018;27(150). Available from: http://dx.doi.org/10.1183/16000617.0077-2018
3. Wälscher J, Witt S, Schwarzkopf L et al. Hospitalisation patterns of patients with interstitial lung disease in the light of comorbidities and medical treatment- A German claims data analysis. Respir Res. 2020;21(1):1–9.
4. Buschulte K, Kabitz H-J, Hagmeyer L et al. Hospitalisation patterns in interstitial lung diseases: data from the EXCITING-ILD registry. Respir Res [Internet]. 2024 Jan 4;25(1):5. Available from: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-023-02588-y
5. Leuschner G, Behr J. Acute exacerbation in interstitial lung disease. Front Med. 2017;4(OCT):1–13.
6. Wang Y, Ji Z, Xu B et al. The incidence of acute exacerbation of idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Sci Rep [Internet]. 2024;14(1):1–10. Available from: https://doi.org/10.1038/s41598-024-71845-x
7. Salonen J, Vähänikkilä H, Purokivi M et al. Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases. Adrish M, editor. PLoS One [Internet]. 2020 Nov 30;15(11):e0242860. Available from: https://dx.plos.org/10.1371/journal.pone.0242860
8. Salonen J, Vähänikkilä H, Purokivi M et al. Causes of acute respiratory hospitalizations predict survival in fibrosing interstitial lung diseases. PLoS One. 2020;15(11 November):1–18.
9. Durheim MT, Judy J, Bender S et al. A retrospective study of in-hospital mortality in patients with idiopathic pulmonary fibrosis between 2015 and 2018. Medicine (Baltimore) [Internet]. 2020 Nov 20;99(47):e23143. Available from: https://journals.lww.com/10.1097/MD.0000000000023143
10. Korogodina A, Kaur N, Xie X et al. The impact of hospitalization on mortality in patients with connective tissue disease-associated interstitial lung disease: a medical records review study. Adv Rheumatol [Internet]. 2024 Jan 2;64(1):1. Available from: https://advancesinrheumatology.biomedcentral.com/articles/10.1186/s42358-023-00343-x
11. Maher TM, Whyte MKB, Hoyles RK et al. Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique. Adv Ther. 2015;32(10):929–43.
12. Collard HR, Ryerson CJ, Corte TJ et al. Acute exacerbation of idiopathic pulmonary fibrosis an international working group report. Am J Respir Crit Care Med. 2016;194(3):265–75.
13. Naccache J-M, Jouneau S, Didier M et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med [Internet]. 2022 Jan;10(1):26–34. Available from: https://linkinghub.elsevier.com/retrieve/pii/S2213260021003544
14. Biondini D, Balestro E, Sverzellati N et al. Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies. Expert Rev Respir Med [Internet]. 2020 Apr 2;14(4):405–14. Available from: https://www.tandfonline.com/doi/full/10.1080/17476348.2020.1724096
15. Office for National Statistics. Census Output Area population estimates – North West, England (supporting information) [Internet]. 2020. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/censusoutputareaestimatesinthenorthwestregionofengland
16. Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the protection of natural persons with regard to the processing of personal data and on the free movement of such data, and repealing Directive 95/46/EC (General Da [Internet].

2016. p. 1–88. Available from: http://data.europa.eu/eli/reg/2016/679/oj
17. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis [Internet]. 1987 Jan;40(5):373–83. Available from: https://linkinghub.elsevier.com/retrieve/pii/0021968187901718
18. UK Government. English indices of deprivation [Internet]. 2019 [cited 2024 Nov 18]. Available from: https://www.gov.uk/government/collections/english-indices-of-deprivation
19. Min B, Grant-Orser A, Johannson KA. Peripheral blood monocyte count and outcomes in patients with interstitial lung disease: a systematic review and meta-analysis. Eur Respir Rev [Internet]. 2023 Sep 30;32(169):230072. Available from: https://publications.ersnet.org/lookup/doi/10.1183/16000617.0072-2023
20. Achaiah A, Rathnapala A, Pereira A et al. Neutrophil lymphocyte ratio as an indicator for disease progression in Idiopathic Pulmonary Fibrosis. BMJ Open Respir Res [Internet]. 2022 Jun 17;9(1):e001202. Available from: https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2022-001202
21. Moua T, Westerly BD, Dulohery MM et al. Patients With Fibrotic Interstitial Lung Disease Hospitalized for Acute Respiratory Worsening. Chest [Internet]. 2016 May;149(5):1205–14. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0012369216004438
22. Collard HR, Ryerson CJ, Corte TJ et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med [Internet]. 2016 Aug 1;194(3):265–75. Available from: https://www.atsjournals.org/doi/10.1164/rccm.201604-0801CI
23. Song JW, Hong S-B, Lim C-M et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J [Internet]. 2011 Feb;37(2):356–63. Available from: https://publications.ersnet.org/lookup/doi/10.1183/09031936.00159709
24. Antoniou KM, Cottin V. The Challenge of Acute Exacerbation of Pulmonary Fibrosis. Respiration [Internet]. 2012;83(1):13–6. Available from: https://karger.com/article/doi/10.1159/000331458
25. Ba C, Wang H, Jiang C et al. Clinical manifestations and prognostic factors analysis of patients hospitalised with acute exacerbation of idiopathic pulmonary fibrosis and other interstitial lung diseases. BMJ Open Respir Res [Internet]. 2024 Feb 27;11(1):e001997. Available from: https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2023-001997
26. Kreuter M, Koegler H, Trampisch M et al. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS® trials. Respir Res [Internet]. 2019 Dec 11;20(1):71. Available from: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-019-1037-7
27. Smith GD, Chaturvedi N, Harding S et al. Ethnic inequalities in health: A review of UK epidemiological evidence. Crit Public Health [Internet]. 2000 Dec;10(4):375–408. Available from: http://www.tandfonline.com/doi/abs/10.1080/09581590010005331
28. Adegunsoye A, Freiheit E, White EN et al. Evaluation of Pulmonary Fibrosis Outcomes by Race and Ethnicity in US Adults. JAMA Netw Open [Internet]. 2023 Mar 10;6(3):e232427. Available from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802255
29. Tikellis G, Holland AE. Health disparities and associated social determinants of health in interstitial lung disease: a narrative review. Eur Respir Rev [Internet]. 2025 Apr 2;34(176):240176. Available from: https://publications.ersnet.org/lookup/doi/10.1183/16000617.0176-2024
30. ONS. Quality of ethnicity data in health-related administrative data sources by sociodemographic characteristics, England: May 2024. 2024;(May):1–6.
31. Lam J, Aldridge R, Blackburn R et al. How is ethnicity reported, described, and analysed in health research in the UK? A bibliographical review and focus group discussions with young refugees. BMC Public Health [Internet]. 2023;23(1):1–11. Available from: https://doi.org/10.1186/s12889-023-16947-3
32. Kreuter M, Bendstrup E, Russell A-M et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med [Internet]. 2017 Dec;5(12):968–80. Available from:

https://linkinghub.elsevier.com/retrieve/pii/S2213260017303831
33. Cassidy N, Fox L, Love M et al. Fibrotic interstitial lung disease - palliative care needs: a World-Café qualitative study. BMJ Support Palliat Care [Internet]. 2024 Dec;14(e3):e2649–56. Available from: https://spcare.bmj.com/lookup/doi/10.1136/bmjspcare-2021-003249
34. Bramhill C, Langan D, Mulryan H et al. Exploration of the unmet needs of patients diagnosed with idiopathic pulmonary fibrosis: a scoping review protocol. BMJ Open [Internet]. 2023 May 2;13(5):e070513. Available from: https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2022-070513
35. Janssen DJA, Bajwah S, Boon MH et al. European Respiratory Society clinical practice guideline: palliative care for people with COPD or interstitial lung disease. Eur Respir J [Internet]. 2023 Aug;62(2):2202014. Available from: https://publications.ersnet.org/lookup/doi/10.1183/13993003.02014-2022
36. Kreuter M, Polke M, Walsh SLF et al. Acute exacerbation of idiopathic pulmonary fibrosis: International survey and call for harmonisation. Eur Respir J [Internet]. 2020;55(4). Available from: http://dx.doi.org/10.1183/13993003.01760-2019
37. National Institute for Health and Care Excellence. Idiopathic pulmonary fibrosis in adults. 2015.
38. British Thoracic Society. BTS ILD Registry Annual Report 2024. 2025;16(1):1–39.
39. Barratt SL, Morales M, Speirs T et al. Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs. BMJ Open Respir Res [Internet]. 2018 Dec;5(1):e000360. Available from: https://bmjopenrespres.bmj.com/lookup/doi/10.1136/bmjresp-2018-000360